A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease
NCT ID: NCT00162032
Last Updated: 2019-07-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
445 participants
INTERVENTIONAL
2005-08-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects
NCT00162045
Cardiovascular Status of Children 5 Years After Kawasaki Disease
NCT03750123
European and North Indian Cohort of KaWasaki dIsease
NCT06305611
Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease
NCT02752191
A Blood Test to Diagnose Kawasaki Disease
NCT05091229
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Children (Ages 4-11)
Children 4-11 years of age, intervention Sestamibi
Sestamibi
Sestamibi
Adolescents (Ages 12-16)
Adolescents 12-16 years of age, intervention Sestamibi
Sestamibi
Sestamibi
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sestamibi
Sestamibi
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meet the epidemiological definition of Kawasaki Disease or have a diagnosis of incomplete KD, including evidence of coronary artery disease as determined by their physician.
* Be able to exercise adequately to achieve 85% age predicted maximum heart rate
Exclusion Criteria
4 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lantheus Medical Imaging
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qi Zhu, MD,
Role: STUDY_DIRECTOR
Lantheus Medical Imaging
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Anchorage, Alaska, United States
Local Institution
Little Rock, Arkansas, United States
Local Institution
Los Angeles, California, United States
Local Institution
Orange, California, United States
Local Institution
San Diego, California, United States
Local Institution
Denver, Colorado, United States
Local Institution
Hartford, Connecticut, United States
Local Institution
New Haven, Connecticut, United States
Local Institution
Honolulu, Hawaii, United States
Local Institution
Chicago, Illinois, United States
Local Institution
Chicago, Illinois, United States
Local Institution
Park Ridge, Illinois, United States
Local Institution
Indianapolis, Indiana, United States
Local Institution
Lexington, Kentucky, United States
Local Institution
Boston, Massachusetts, United States
Local Institution
Las Vegas, Nevada, United States
Local Institution
New Hyde Park, New York, United States
Local Institution
New York, New York, United States
Local Institution
Durham, North Carolina, United States
Local Institution
Greenville, North Carolina, United States
Local Institution
Cincinnati, Ohio, United States
Local Institution
Cleveland, Ohio, United States
Local Institution
Hershey, Pennsylvania, United States
Local Institution
Philadelphia, Pennsylvania, United States
Local Institution
Pittsburgh, Pennsylvania, United States
Local Institution
Charlottesville, Virginia, United States
Local Institution
Seattle, Washington, United States
Local Institution
Spokane, Washington, United States
Local Institution
Milwaukee, Wisconsin, United States
Local Institution
Belo Horizonte, , Brazil
Local Institution
Campinas, , Brazil
Local Institution
Curitiba, , Brazil
Local Institution
Rio de Janeiro, , Brazil
Local Institution
São Paulo, , Brazil
Local Institution
Vancouver, British Columbia, Canada
Local Institution
Halifax, Nova Scotia, Canada
Local Institution
Toronto, Ontario, Canada
Local Institution
Montreal, Quebec, Canada
Local Institution
Quezon City, , Philippines
Local Institution
Daejeon, , South Korea
Local Institution
Pusan, , South Korea
Local Insitution
Seoul, , South Korea
Local Institution
Suwon, , South Korea
Local Institution
Wŏnju, , South Korea
Local Institution
Changhua, , Taiwan
Local Institution
Kaohsiung City, , Taiwan
Local Institution
Taichung, , Taiwan
Local Institution
Taipei, , Taiwan
Local Institution
Bangkok, , Thailand
Local Institution
Hat Yai, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CARDIOLITE® 301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.